Axitinib-related osteonecrosis of the jaw
| Autor: | Chris Sproat, Vinod Patel, Jerry Kwok, Nikki Tanna |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Oncology Pathology medicine.medical_specialty Indazoles Necrosis Stromal cell Axitinib Neuroendocrine tumors Conservative Treatment Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine stomatognathic system Renal cell carcinoma Internal medicine Radiography Panoramic Carcinoma Humans Medicine Radiology Nuclear Medicine and imaging Dentistry (miscellaneous) Carcinoma Renal Cell Protein Kinase Inhibitors Aged business.industry Imidazoles Osteonecrosis 030206 dentistry medicine.disease Kidney Neoplasms Maxillary Diseases respiratory tract diseases stomatognathic diseases 030220 oncology & carcinogenesis Surgery Oral Surgery medicine.symptom business Osteonecrosis of the jaw Tyrosine kinase medicine.drug |
| Zdroj: | Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 124:e257-e260 |
| ISSN: | 2212-4403 |
| DOI: | 10.1016/j.oooo.2017.08.003 |
| Popis: | Tyrosine kinase inhibitors (TKIs) are oral chemotherapy drugs used primarily to treat leukemias, renal cell carcinomas, gastrointestinal stromal tumors, and neuroendocrine tumors. Within this group, a number of drugs have already been implicated in jaw necrosis. Axitinib (Inlyta) is a novel TKI currently licensed for the treatment of renal cell carcinoma. We report the first case, to our knowledge, of jaw necrosis solely related to this medication and review the literature surrounding TKIs and their implication in osteonecrosis of the jaw. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect